Effects of P5, a novel oxazolo(3,2-a)pyridine derivative with a long-acting antihypertensive activity, on different agonist-mediated pressor responses in pithed rats
E. Martín
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorM. A. Sevilla
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorA. Morán
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorM. L. Martín
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorL. San Román
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorE. Martín
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorM. A. Sevilla
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorA. Morán
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorM. L. Martín
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorL. San Román
Departamento de Fisiología y Farmacología, Laboratorio de Farmacognosia y Farmacología, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Spain
Search for more papers by this authorAbstract
1 An oxazolo(3,2-a)pyridine derivative P5, described chemically as (±)-ethyl-7-(3-nitrophenyl)-5,8a-dimethyl-6-methoxycarbonyl-2,3,8,8a-tetrahydro-7H-oxazolo[3,2-a]pyridin-8-carboxylate, is a novel compound that has been synthesized as a possible antihypertensive prodrug of the 1,4-dihydropyridine type. Its antihypertensive activity was described in a previous study by the authors (Morán, Martin, Velasco, Martin, San Roman, Caballero, Puebla, Medarde & San Feliciano, 1997).
2 The aim of this work was to establish in vivo, the possible mechanisms participating in this antihypertensive action. Accordingly, we examined the effect of P5 on the pressor responses induced in pithed rats by noradrenaline (an α1-, α2- and β-adrenoceptor agonist), xylazine (an α2-adrenoceptor agonist), methoxamine (an α1-adrenoceptor agonist), angiotensin I, angiotensin II, L-NAME (a nitric oxide synthase inhibitor) and BayK 8644 (a calcium channel agonist) and compared them with those of nifedipine, used as the reference drug.
3 Intravenous (i.v.) administration of P5 (2.5–10 mg kg–1) inhibited the pressor responses to noradrenaline (1 μg kg–1), xylazine (80 μg kg–1), angiotensin I (0.5 μg kg–1), angiotensin II (0.5 μg kg–1), BayK 8644 (30 μg kg–1) and L-NAME (10 mg kg–1). Nifedipine (10 μg kg–1, i.v.) reduced the pressor responses to all these agonists and also to methoxamine (2 μg kg–1).
4 However, P5 was more effective than nifedipine in inhibiting these responses and its inhibitory effect lasted longer. Intravenous infusion of calcium gluconate (1 ml kg–1 min–1) reversed the reduction in the pressor responses as a result of nifedipine. The effects of P5 were only reversed at 2–3 h after administration.
5 These results suggest that P5 has a strong capacity to inhibit the pressor responses to several agonists after its i.v. administration and that such effects are related to its potent antihypertensive activity.
References
- 1 Aleixandre, M.A., Puerro, M., Pintado, A. (1995). A comparison of the effects of TMP-8 and nifedipine on pressor responses to α1- and α2-adrenoceptor agonists in pithed rats. Naunyn-Schmiedeberg’s Arch. Pharmacol., 351 , 500–506.
- 2 Caballero, E., Puebla, P., Medarde, M., San Feliciano, A. (1993). Regiochemistry in the synthesis of 2,3,8,8a-tetrahydro-7H-oxazolo[3,2a]pyridines. Tetrahedron, 49 , 10 079–10 088.
- 3 Cardelús, I., Bou, J., Berga, P., Gristwood, R.W. (1992). Cardiovascular effects of LAS 30538, a new vascular selective Ca2+-channel blocker. J. Pharm. Pharmacol., 44 , 830–835.
- 4 Chalmers, J., MacMahon, S., Mancia, G, Whitworth, J., Beilen, L., Hansson, L., Neal, B., Rodgers, A., Mhurchu, C.N., Clark, T. (1999). WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens., 17 , 151–185.
- 5 Clapham, J.C. (1988). A method for in vivo assessment of calcium slow channel blocking drugs. J. Cardiovasc. Pharmacol., 11 , 56–60.
- 6 Flavahan, N.A. & Mcgrath, J.C. (1980). Blockade by yohimbine of prazosin resistant pressor effects of adrenaline in the pithed rat. Br. J. Pharmacol., 69 , 355–357.
- 7 Gardiner, S.M., Compton, A.M., Kemp, P.A., Bennett, T. (1990). Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol., 101 , 625–631.
- 8 Gillespie, J.C. & Muir, T.C. (1967). A method of stimulating the complete sympathetic outflow from spinal cord to blood vessels in the pithed rats. Br. J. Pharmacol., 30 , 78–87.
- 9 Hansson, L. & Himmelmann, A. (1991). Calcium antagonists in antihypertensive combination therapy. J. Cardiovasc. Pharmacol., 18 , S76–S80.
- 10 Ichihara, K., Okumura, K., Mori, H., Nagasaka, M. (1993). Effects of MPC-1034, a novel Ca2+ entry blocker, on α-adrenoceptor-mediated pressor responses in pithed rats. Eur. J. Pharmacol., 238 , 283–289.
- 11 Ikeno, A., Nose, I., Fukuya, F., Minato, H., Takeyama, K., Hosoki, K., Karasawa, T. (1993). Antihypertensive effects of AJ-2615, a new calcium antagonist with α1-adrenergic blocking activity in experimental hypertensive animals. J. Cardiovasc. Pharmacol., 21 , 815–821.
- 12 Izumi, H., Jinno, Y., Kaneta, S., Tanaka, Y., Okada, Y., Izawa, T., Ogawa, N. (1995). Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalin, nivaldipine and nifedipine. J. Cardiovasc. Pharmacol., 26 , 189–197.
- 13 JOINT NATIONAL COMMITTEE (1998). The 1988 Report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. >Arch. Intern. Med., 148 , 1023–1038.
- 14 Jonsson, J.R., Smid, S.D., Frewin, D.B., Head, R.J. (1993). Angiotensin II-mediated facilitation of sympathetic neurotransmission in the spontaneously hypertensive rat is not associated with neuronal uptake of the peptide. J. Cardiovasc. Pharmacol., 22 , 750–753.
- 15 Kanda, A., Haruno, A., Miyoshi, Y., Tanahashi, H., Miyake, H., Ichihara, K., Okumura, K., Nagasaka, M. (1993). Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists. J. Cardiovasc. Pharmacol., 22 , 167–175.
- 16 Kaplan, M.K. (1994). Clinical Hypertension. Ed. Williams & Wilkins, Baltimore.
- 17 Kyles, A.E., Waterman, A.E., Livingston, A. (1993). The spinal antinociceptive activity of the α2-adrenoceptor agonist, xylazine in sheep. Br. J. Pharmacol., 108 , 907–913.
- 18 Lew, M.J. & Angus, J.A. (1985). α1- and α2-adrenoceptor-mediated pressor responses: are they differentiated by calcium antagonists or by functional antagonism? J. Cardiovasc. Pharmacol., 7 , 401–408.
- 19 Martin, E., Moran, A., Martin, M.L., San Roman, L., Puebla, P., Medarde, M., Caballero, E., San Feliciano, A. (2000). Antihypertensive effect of substituted 2,3,8,8ª-tetrahydro-7H-oxazolo[3,2-a]pyridinecarboxylate enantiomers. Biorg. Med. Chem. Lett., 10 , 319–322.
- 20 Midtbo, K. & Hals, O. (1987). Can blood pressure reduction induced by slow calcium channel blockade (verapamil) be reversed by calcium infusion? Pharmacol. Toxicol., 60 , 330–332.
- 21 Moir, M. & Holbrook, R.H. (1993). Effect of nicardipine on the reversal of magnesium toxicity by calcium gluconate in non-pregnant rabbits. Obstet-Gynecol., 82 , 67–70.
- 22 Morán, A., Martín, E., Velasco, C., Martín, M.L., San Román, L., Caballero, E., Puebla, P., Medarde, M., San Feliciano, A. (1997). Antihypertensive effect of some oxazolo[3,2-a]pyridines, thiazolo[3,2-a]pyridines and pyrido[2,1-boxazines in conscious spontaneously hypertensive rats. J. Pharm. Pharmacol., 49 , 421–425.
- 23 Nakayama, N., Ikezono, K., Mori, T., et al. (1990). Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats. J. Cardiovasc. Pharmacol., 15 , 836–844.
- 24 Okamura, H., Fujitani, B., Furukawa, K., Une, T., Nukuda, T., Komiya, M., Kurokawa, M. (1993). Pharmacological properties of a novel Ca2+ entry blocker, AJ-2615, in vitro. J. Cardiovasc. Pharmacol., 22 , 804–809.
- 25 Ruffolo, R.R., Nichols, A.J., Stadel, J.M., Hieble, J.P. (1991). Structure and function of α-adrenoceptors. Pharmacol. Rev., 43 , 475–505.
- 26 San Feliciano, A., Caballero, E., Pereira, J.A.P., Puebla, P. (1991). 2,3,8,8a-tetrahydro-7H-oxazolo[3,2a]pyridine: a new heterocyclic system. Tetrahedron, 47 , 6503–6510.DOI: 10.1016/S0040-4020(01)86577-7
- 27 Shinyama, H., Nagai, H., Kawamura, T., Narita, Y., Uchida, T., Watanabe, M., Kagitani, Y. (1995). Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats. J. Pharmacol. Exp. Ther., 272 , 911–919.
- 28 Sironi, G., Montagna, E., Greto, L., Bianchi, G., Leonardi, A., Testa, R. (1996). Antihypertensive effects of lecarnidipine in experimental hypertensive rats and dogs. Arzneim-Forsch Drug. Res., 46 , 145–152.
- 29 Sponer, G., Borbe, H.O., Müller-Beckmann, B., Frued, P., Jakob, B. (1992). Naftopidil, a new adrenoceptor blocking agent with Ca2+-antagonistic properties: interaction with adrenoceptors. J. Cardiovasc. Pharmacol., 20 , 1006–1013.
- 30 Sugimoto, T., Hosiki, K., Karasawa, T. (1995). Relative contribution of α1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil. J. Cardiovasc. Pharmacol., 26 , 55–60.
- 31 Swales, J.D. (1994). The renin–angiotensin system as a target for therapeutic intervention. J. Cardiovasc. Pharmacol., 24 , S1–S5.
- 32 Van Heiningen, P.M. & Van Zwieten, P.A. (1988). Differential sensitivity to calcium entry blockade of angiotensin II-induced contractions of rat and guinea-pig aorta. Arch. Int. Pharmacodyn. Ther., 296 , 118–130.
- 33 Van Meel, J.C.A., De Jonge, A., Kalkman, N.O., Wilffert, B., Timmermans, P.B.M.W.M., Van Zwieten, P.A. (1981). Organic and inorganic calcium antagonists reduce vasoconstriction in vivo mediated by postsynaptic α2 adrenoceptors. Naunyn-Schmiedeberg’s Arch. Pharmacol., 316 , 288–293.
- 34 Van Zwieten, P.A. & Timmermans, P.B.M.W.M. (1987). Alpha-adrenoceptor stimulation and calcium movements. Blood Vessels, 24 , 271–280.
- 35 Van Zwieten, P.A., Timmermans, P.B., Van Heiningen, P.N. (1987). Receptor subtypes involved in the action of calcium antagonists. J. Hypertens., 5 , S21–S28.
- 36 Van Zwieten, P.A., Van Meel, J.C.A., Timmermans, P.B.M.W.M. (1982). Calcium antagonists and α2-adrenoceptor: possible role of extracellular calcium ions in mediated α2-adrenoceptor-mediated vasoconstriction. J. Cardiovasc. Pharmacol., 4 , S273–S279.
- 37 Yamaguchi, I. & Kopin, I.J. (1980). Differential inhibition of alpha-1 and alpha-2 adrenoceptor mediated pressor responses in pithed rats. J. Pharmacol. Exp. Ther., 214 , 275–281.
